JOP20170135A1 - مركبات ديازاسبيروألكيل مثيل-إندول - Google Patents

مركبات ديازاسبيروألكيل مثيل-إندول

Info

Publication number
JOP20170135A1
JOP20170135A1 JOJO/P/2017/0135A JOP20170135A JOP20170135A1 JO P20170135 A1 JOP20170135 A1 JO P20170135A1 JO P20170135 A JOP20170135 A JO P20170135A JO P20170135 A1 JOP20170135 A1 JO P20170135A1
Authority
JO
Jordan
Prior art keywords
compounds
diazaspiroalkylmethyl
preparation
pharmaceutical formulations
indoles
Prior art date
Application number
JOJO/P/2017/0135A
Other languages
English (en)
Inventor
Ter Laak Antonius
Siegel Stephan
Haendler Bernard
STRESEMANN Carlo
Ernesto Fernandez-Montalvan Amaury
Stockigt Detlef
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of JOP20170135A1 publication Critical patent/JOP20170135A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات diazaspiroalkylmethyl-indole بالصيغة العامة (I): (I) حيث يكون R8، X و Y كمت عرف هنا، وطريق لتحضير المركبات المذكورة، ومركبات وسيطة مفيدة لتحضير المركبات المذكورة، وتراكيب صيدلية وتوليفات تشمل المركبات المذكورة واستخدام المركبات المذكورة لتصنيع تراكيب صيدلية للمعالجة أو الوقاية من الأمراض، تحديدا السرطان، في صور عامل لوحده أو في توليفة مع مكونات فعالة اخرى.
JOJO/P/2017/0135A 2016-05-31 2017-05-30 مركبات ديازاسبيروألكيل مثيل-إندول JOP20170135A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16172216 2016-05-31
EP16205809 2016-12-21

Publications (1)

Publication Number Publication Date
JOP20170135A1 true JOP20170135A1 (ar) 2017-11-30

Family

ID=58745252

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2017/0135A JOP20170135A1 (ar) 2016-05-31 2017-05-30 مركبات ديازاسبيروألكيل مثيل-إندول

Country Status (2)

Country Link
JO (1) JOP20170135A1 (ar)
WO (1) WO2017207387A1 (ar)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
US12084462B2 (en) * 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
EP3512857B1 (en) * 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
CN110248946B (zh) 2016-12-15 2023-05-23 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
JP7307729B2 (ja) * 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
ES2991898T3 (es) * 2018-08-08 2024-12-05 Sumitomo Pharma Co Ltd Derivado de piperidina con puente ópticamente activo
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
US20240417405A1 (en) 2021-05-08 2024-12-19 Janssen Pharmaceutica Nv Substituted Spiro Derivatives
CA3215379A1 (en) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Substituted spiro derivatives
IL308862A (en) 2021-06-01 2024-01-01 Janssen Pharmaceutica Nv Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
JP2024521902A (ja) 2021-06-03 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
WO2022262796A1 (en) 2021-06-17 2022-12-22 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN120379996A (zh) * 2022-08-11 2025-07-25 瑞敏德股份有限公司 用于治疗神经退行性障碍的(氮杂)螺庚烷衍生物
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4562799A (en) 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JPWO2005047286A1 (ja) 2003-11-13 2007-05-31 小野薬品工業株式会社 スピロ複素環化合物
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
WO2008033447A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
CA2663500A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US9212180B2 (en) 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
WO2014200479A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物

Also Published As

Publication number Publication date
WO2017207387A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
JOP20170135A1 (ar) مركبات ديازاسبيروألكيل مثيل-إندول
JOP20230073A1 (ar) بنزاميدات مستبدلة مع 3،1- ثيازول-2- يل
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
DOP2019000117A (es) Nuevos derivados de quinolina
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX389697B (es) Nuevos derivados de pirazolopirimidina.
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12020500134A1 (en) Dihydrooxadiazinones
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
DOP2016000253A (es) Nuevos compuestos
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
NZ708821A (en) Lfa-1 inhibitor formulations
PH12017501133A1 (en) Pyrazolopyridinamines
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
JOP20170127A1 (ar) صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات